International Journal of Molecular Sciences Review WNT Signaling as a Therapeutic Target for Glioblastoma Michael Latour 1,†, Nam-Gu Her 2,†, Santosh Kesari 1 and Elmar Nurmemmedov 1,* 1 Saint John’s Cancer Institute at Providence Saint John’s Health Center, Santa Monica, CA 90404, USA;
[email protected] (M.L.);
[email protected] (S.K.) 2 Samsung Medical Center, Seoul 135-710, Korea;
[email protected] * Correspondence:
[email protected] † Equally contributing author. Abstract: The WNT (Wingless/Integrated) signaling pathway is implicated in various stages of glioblastoma, which is an aggressive brain tumor for which therapeutic options are limited. WNT has been recognized as a hallmark of therapeutic challenge due to its context-dependent role and critical function in healthy tissue homeostasis. In this review, we deeply scrutinize the WNT signaling pathway and its involvement in the genesis of glioblastoma as well as its acquired therapy resistance. We also provide an analysis of the WNT pathway in terms of its therapeutic importance in addition to an overview of the current targeted therapies under clinical investigation. Keywords: glioblastoma; WNT; beta-catenin; therapeutic; drug; resistance 1. Biology of WNT Signaling WNT (Wingless/Integrated) signaling regulates key cellular events during the devel- opment of the central nervous system. Particularly, it regulates self-renewal, differentiation, Citation: Latour, M.; Her, N.-G.; migration and signaling of neural stem cells in the fetal ventricular zone, the postnatal Kesari, S.; Nurmemmedov, E. WNT subventricular zone and the hippocampus [1,2]. It has been abundantly demonstrated that Signaling as a Therapeutic Target for hyperactivation of WNT signaling is associated with driving malignant transformation and Glioblastoma.